112 related articles for article (PubMed ID: 35648731)
1. Comparing Two Databases to Identify Access to Buprenorphine Treatment for Opioid Use Disorder.
Anyanwu P; Varisco TJ; Wanat MA; Bapat S; Claborn K; Thornton JD
J Pain Palliat Care Pharmacother; 2022 Jun; 36(2):103-111. PubMed ID: 35648731
[TBL] [Abstract][Full Text] [Related]
2. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
Andrilla CHA; Moore TE; Patterson DG; Larson EH
J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
[TBL] [Abstract][Full Text] [Related]
3. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.
Andrilla CHA; Patterson DG
J Rural Health; 2022 Jan; 38(1):87-92. PubMed ID: 33733547
[TBL] [Abstract][Full Text] [Related]
4. Broadband access and telemedicine adoption for opioid use disorder treatment in the United States.
Ali MM; Ghertner R
J Rural Health; 2023 Jan; 39(1):233-239. PubMed ID: 35838414
[TBL] [Abstract][Full Text] [Related]
5. Comparison between buprenorphine provider availability and opioid deaths among US counties.
Jones CW; Christman Z; Smith CM; Safferman MR; Salzman M; Baston K; Haroz R
J Subst Abuse Treat; 2018 Oct; 93():19-25. PubMed ID: 30126537
[TBL] [Abstract][Full Text] [Related]
6. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.
Ghertner R
Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570
[TBL] [Abstract][Full Text] [Related]
7. Opting into the Public List of DATA-Waivered Practitioners: Variations by Specialty, Treatment Capacity, and Practitioner Characteristics.
Nguyen T; Andraka-Christou B; Bradford WD; Simon K
J Addict Med; 2022 May-Jun 01; 16(3):e197-e202. PubMed ID: 34669615
[TBL] [Abstract][Full Text] [Related]
8. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
[TBL] [Abstract][Full Text] [Related]
9. Trends in buprenorphine-waivered providers in Medicaid expansion and non-expansion states by their public listing status.
Sanmartin MX; Ali MM; Dwyer DS
Subst Abus; 2022 Dec; 43(1):1072-1074. PubMed ID: 35442126
[No Abstract] [Full Text] [Related]
10. Geographic access to buprenorphine prescribers for patients who use public transit.
Drake C; Donohue JM; Nagy D; Mair C; Kraemer KL; Wallace DJ
J Subst Abuse Treat; 2020 Oct; 117():108093. PubMed ID: 32811632
[TBL] [Abstract][Full Text] [Related]
11. Availability of Buprenorphine Treatment in the 10 States With the Highest Drug Overdose Death Rates in the United States.
Flavin L; Malowney M; Patel NA; Alpert MD; Cheng E; Noy G; Samuelson S; Sreshta N; Boyd JW
J Psychiatr Pract; 2020 Jan; 26(1):17-22. PubMed ID: 31913966
[TBL] [Abstract][Full Text] [Related]
12. Medicaid participation among practitioners authorized to prescribe buprenorphine.
Saunders H; Britton E; Cunningham P; Saxe Walker L; Harrell A; Scialli A; Lowe J
J Subst Abuse Treat; 2022 Feb; 133():108513. PubMed ID: 34148758
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of publicly-listed locator information for buprenorphine waivered practitioners and opioid treatment programs in the US, 2020.
Barenie RE; Winbigler BL; Heidel RE; Wheeler JS
Subst Abus; 2022; 43(1):999-1003. PubMed ID: 35435809
[No Abstract] [Full Text] [Related]
14. A comparison of methods for measuring spatial access to health care.
Drake C; Nagy D; Nguyen T; Kraemer KL; Mair C; Wallace D; Donohue J
Health Serv Res; 2021 Oct; 56(5):777-787. PubMed ID: 34250592
[TBL] [Abstract][Full Text] [Related]
15. County-level access to opioid use disorder medications in medicare Part D (2010-2015).
Abraham AJ; Adams GB; Bradford AC; Bradford WD
Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272
[TBL] [Abstract][Full Text] [Related]
16. The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States.
Stringfellow EJ; Lim TY; Dong H; Zhang Z; Jalali MS
Addiction; 2023 Nov; 118(11):2215-2219. PubMed ID: 37434347
[TBL] [Abstract][Full Text] [Related]
17. Are DEA-waivered buprenorphine prescribers colocated with behavioral health clinicians?
Zerden LS; Sullivan C; Galloway E; Richman EL; Gaiser MG; Lombardi B
Am J Addict; 2023 Nov; 32(6):574-583. PubMed ID: 37559344
[TBL] [Abstract][Full Text] [Related]
18. Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX.
Potter JS; Finley EP; King VL; Lanham HJ; Schmidt S; Schneegans S; Rosen KD
J Subst Abuse Treat; 2022 Jun; 137():108688. PubMed ID: 35058105
[TBL] [Abstract][Full Text] [Related]
19. Spatial access to buprenorphine-waivered prescribers in the HEALing communities study: Enhanced 2-step floating catchment area analyses in Massachusetts, Ohio, and Kentucky.
Shrestha S; Lindstrom MR; Harris D; Rock P; Srinivasan S; Pustz JC; Bayly R; Stopka TJ
J Subst Use Addict Treat; 2023 Jul; 150():209077. PubMed ID: 37211155
[TBL] [Abstract][Full Text] [Related]
20. Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.
Dick AW; Pacula RL; Gordon AJ; Sorbero M; Burns RM; Leslie D; Stein BD
Health Aff (Millwood); 2015 Jun; 34(6):1028-34. PubMed ID: 26056209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
